Hostname: page-component-cd9895bd7-7cvxr Total loading time: 0 Render date: 2024-12-23T00:59:16.243Z Has data issue: false hasContentIssue false
  • English
  • Français

No evidence of associations between genetic liability for schizophrenia and development of cannabis use disorder

Published online by Cambridge University Press:  09 December 2019

Carsten Hjorthøj Open the ORCID record for Carsten Hjorthøj [Opens in a new window] ,
Md Jamal Uddin ,
Theresa Wimberley ,
Søren Dalsgaard ,
David M. Hougaard ,
Anders Børglum ,
Thomas Werge  and
Merete Nordentoft
Carsten Hjorthøj*
Affiliation:
Copenhagen Research Center for Mental Health – CORE, Mental Health Center Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark The Lundbeck Foundation Initiative for Integrative Psychiatric Research (iPSYCH), Copenhagen and Aarhus, Denmark Department of Public Health, Section of Epidemiology, University of Copenhagen, Copenhagen, Denmark
Md Jamal Uddin
Affiliation:
Copenhagen Research Center for Mental Health – CORE, Mental Health Center Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark The Lundbeck Foundation Initiative for Integrative Psychiatric Research (iPSYCH), Copenhagen and Aarhus, Denmark
Theresa Wimberley
Affiliation:
The Lundbeck Foundation Initiative for Integrative Psychiatric Research (iPSYCH), Copenhagen and Aarhus, Denmark Department of Economics and Business Economics, NCRR-The National Centre for Register-Based Research, Aarhus BSS, Aarhus University, Aarhus, Denmark CIRRAU-Centre for Integrated Register-Based Research, Aarhus University, Aarhus, Denmark
Søren Dalsgaard
Affiliation:
The Lundbeck Foundation Initiative for Integrative Psychiatric Research (iPSYCH), Copenhagen and Aarhus, Denmark Department of Economics and Business Economics, NCRR-The National Centre for Register-Based Research, Aarhus BSS, Aarhus University, Aarhus, Denmark
David M. Hougaard
Affiliation:
The Lundbeck Foundation Initiative for Integrative Psychiatric Research (iPSYCH), Copenhagen and Aarhus, Denmark Department for Congenital Disorders, Center for Neonatal Screening, Statens Serum Institute, Copenhagen, Denmark
Anders Børglum
Affiliation:
The Lundbeck Foundation Initiative for Integrative Psychiatric Research (iPSYCH), Copenhagen and Aarhus, Denmark Institute of Human Genetics, University of Aarhus, Aarhus, Denmark
Thomas Werge
Affiliation:
The Lundbeck Foundation Initiative for Integrative Psychiatric Research (iPSYCH), Copenhagen and Aarhus, Denmark Research Institute of Biological Psychiatry, Mental Health Center Sanct Hans, Copenhagen University Hospital, Roskilde, Denmark
Merete Nordentoft
Affiliation:
Copenhagen Research Center for Mental Health – CORE, Mental Health Center Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark The Lundbeck Foundation Initiative for Integrative Psychiatric Research (iPSYCH), Copenhagen and Aarhus, Denmark
*
Author for correspondence: Carsten Hjorthøj, E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Background

Cannabis use and cannabis use disorder (CUD) is increased in patients with schizophrenia. It is important to establish if this is explained by non-causal factors, such as shared genetic vulnerability. We aimed to investigate whether the polygenic risk scores (PRS) for schizophrenia and other psychiatric disorders would predict CUD in controls, patients with schizophrenia, and patients with other psychiatric disorders.

Methods

We linked nationwide Danish registers and genetic information obtained from dried neonatal bloodspots in an observational analysis. We included people with schizophrenia, other psychiatric disorders, and controls. The exposures of interest were the PRS for schizophrenia, attention-deficit hyperactivity disorder (ADHD) autism spectrum disorder, and anorexia nervosa. The main outcome of interest was the diagnosis of CUD.

Results

The study included 88 637 individuals. PRS for schizophrenia did not predict CUD in controls [hazard ratio (HR) = 1.16, 95% CI 0.95–1.43 per standard-deviation increase in PRS, or HR = 1.47, 95% CI 0.72–3.00 comparing highest v. remaining decile], but PRS for ADHD did (HR = 1.27, 95% CI 1.08–1.50 per standard-deviation increase, or HR = 2.02, 95% CI 1.27–3.22 for the highest decile of PRS). Among cases with schizophrenia, the PRS for schizophrenia was associated with CUD. While CUD was a strong predictor of schizophrenia (HR = 4.91, 95% CI 4.36–5.53), the inclusion of various PRS did not appreciably alter this association.

Conclusion

The PRS for schizophrenia was not associated with CUD in controls or patients with other psychiatric disorders than schizophrenia. This speaks against the hypothesis that shared genetic vulnerability would explain the association between cannabis and schizophrenia.

Keywords

Cannabisgeneticspleiotropypolygenic riskschizophrenia
Type
Original Articles
Information
Psychological Medicine , Volume 51 , Issue 3 , February 2021 , pp. 479 - 484
Check for updates
Copyright
Copyright © Cambridge University Press 2019

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Carey, C. E., Agrawal, A., Bucholz, K. K., Hartz, S. M., Lynskey, M. T., Nelson, E. C., … Bogdan, R. (2016). Associations between polygenic risk for psychiatric disorders and substance involvement. Frontiers in Genetics, 7, 149.CrossRefGoogle ScholarPubMed
Centonze, D., Bari, M., Di Michele, B., Rossi, S., Gasperi, V., Pasini, A., … Maccarrone, M. (2009). Altered anandamide degradation in attention-deficit/hyperactivity disorder. Neurology, 72, 1526–1527.CrossRefGoogle ScholarPubMed
Cerdá, M., Wall, M., Feng, T., Keyes, K. M., Sarvet, A., Schulenberg, J., … Hasin, D. S. (2017). Association of state recreational marijuana laws with adolescent marijuana use. JAMA Pediatrics, 171, 142–149.CrossRefGoogle ScholarPubMed
Compton, W. M., Grant, B. F., Colliver, J. D., Glantz, M. D., & Stinson, F. S. (2004). Prevalence of marijuana use disorders in the United States: 1991–1992 and 2001–2002. JAMA, 291, 2114–2121.CrossRefGoogle ScholarPubMed
Crespi, B., Stead, P., & Elliot, M. (2010). Comparative genomics of autism and schizophrenia. Proceedings of the National Academy of Sciences, 107, 1736–1741.CrossRefGoogle Scholar
Demontis, D., Rajagopal, V. M., Thorgeirsson, T. E., Als, T. D., Grove, J., Leppälä, K., … Børglum, A. D. (2019). Genome-wide association study implicates CHRNA2 in cannabis use disorder. Nature Neuroscience, 22, 1066–1074.CrossRefGoogle ScholarPubMed
Ferdinand, R. F., Sondeijker, F., van der Ende, J., Selten, J.-P., Huizink, A., & Verhulst, F. C. (2005). Cannabis use predicts future psychotic symptoms, and vice versa. Addiction (Abingdon, England), 100, 612–618.CrossRefGoogle ScholarPubMed
Fergusson, D. M., & Boden, J. M. (2008). Cannabis use and adult ADHD symptoms. Drug and Alcohol Dependence, 95, 90–96.CrossRefGoogle ScholarPubMed
Gandal, M. J., Haney, J. R., Parikshak, N. N., Leppa, V., Ramaswami, G., Hartl, C., … Geschwind, D. H. (2018). Shared molecular neuropathology across major psychiatric disorders parallels polygenic overlap. Science, 359, 693–697.CrossRefGoogle ScholarPubMed
Grove, J., Ripke, S., Als, T. D., Mattheisen, M., Walters, R. K., Won, H., … Børglum, A. D. (2019). Identification of common genetic risk variants for autism spectrum disorder. Nature Genetics, 51, 431–444.CrossRefGoogle ScholarPubMed
Hiemstra, M., Nelemans, S. A., Branje, S., van Eijk, K. R., Hottenga, J.-J., Vinkers, C. H., … Boks, M. P. (2018). Genetic vulnerability to schizophrenia is associated with cannabis use patterns during adolescence. Drug and Alcohol Dependence, 190, 143–150.CrossRefGoogle ScholarPubMed
Hjorthøj, C., Uddin, M. J., Hougaard, D. M., Sørensen, H. J., & Nordentoft, M. (2019). Polygenic risk for psychiatric disorder and singleness in patients with severe mental illness and controls. Journal of Psychiatric Research, 119, 60–66.CrossRefGoogle ScholarPubMed
Kühl, J. O. G., Laursen, T. M., Thorup, A., & Nordentoft, M. (2016). The incidence of schizophrenia and schizophrenia spectrum disorders in Denmark in the period 2000–2012. A register-based study. Schizophrenia Research, 176, 533–539.CrossRefGoogle ScholarPubMed
Lee, S. H., Ripke, S., Neale, B. M., Faraone, S. V., Purcell, S. M., Perlis, R. H., … Wray, N. R. (2013). Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nature Genetics, 45, 984–994.Google ScholarPubMed
Lynge, E., Sandegaard, J. L., & Rebolj, M. (2011). The Danish National Patient Register. Scandinavian Journal of Public Health, 39, 30–33.CrossRefGoogle ScholarPubMed
Macleod, J., Oakes, R., Copello, A., Crome, I., Egger, M., Hickman, M., … Davey Smith, G. (2004). Psychological and social sequelae of cannabis and other illicit drug use by young people: a systematic review of longitudinal, general population studies. Lancet, 363, 1579–1588.CrossRefGoogle Scholar
Marconi, A., Di Forti, M., Lewis, C. M., Murray, R. M., & Vassos, E. (2016). Meta-analysis of the association between the level of Cannabis use and risk of psychosis. Schizophrenia Bulletin, 42, 1262–1269.CrossRefGoogle ScholarPubMed
Mehmedic, Z., Chandra, S., Slade, D., Denham, H., Foster, S., Patel, A. S., … ElSohly, M. A. (2010). Potency trends of Δ9-THC and other cannabinoids in confiscated cannabis preparations from 1993 to 2008. Journal of Forensic Sciences, 55, 1209–1217.CrossRefGoogle ScholarPubMed
Meier, S. M., Agerbo, E., Maier, R., Pedersen, C. B., Lang, M., Grove, J., … Mattheisen, M. (2016). High loading of polygenic risk in cases with chronic schizophrenia. Molecular Psychiatry, 21, 969–974.CrossRefGoogle ScholarPubMed
Moore, T. H. M., Zammit, S., Lingford-Hughes, A., Barnes, T. R. E., Jones, P. B., Burke, M., & Lewis, G. (2007). Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet, 370, 319–328.CrossRefGoogle ScholarPubMed
Mors, O., Perto, G. P., & Mortensen, P. B. (2011). The Danish Psychiatric Central Research Register. Scandinavian Journal of Public Health, 39, 54–57.CrossRefGoogle ScholarPubMed
Nielsen, S. M., Toftdahl, N. G., Nordentoft, M., & Hjorthøj, C. (2017). Association between alcohol, cannabis, and other illicit substance abuse and risk of developing schizophrenia: a nationwide population based register study. Psychological Medicine, 47, 1668–1677.CrossRefGoogle ScholarPubMed
Ottosen, C., Petersen, L., Larsen, J. T., & Dalsgaard, S. (2016). Gender differences in associations between attention-deficit/hyperactivity disorder and substance use disorder. Journal of the American Academy of Child & Adolescent Psychiatry, 55, 227–234.CrossRefGoogle ScholarPubMed
Pasman, J. A., Verweij, K. J. H., Gerring, Z., Stringer, S., Sanchez-Roige, S., Treur, J. L., … Vink, J. M. (2018). GWAS of lifetime cannabis use reveals new risk loci, genetic overlap with psychiatric traits, and a causal effect of schizophrenia liability. Nature Neuroscience, 21, 1161–1170.CrossRefGoogle Scholar
Pasman, J. A., Verweij, K. J. H., & Vink, J. M. (2019). Systematic review of polygenic gene–environment interaction in Tobacco, Alcohol, and Cannabis Use. Behavior Genetics, 49, 349–365.CrossRefGoogle ScholarPubMed
Pedersen, C. B., Bybjerg-Grauholm, J., Pedersen, M. G., Grove, J., Agerbo, E., Bækvad-Hansen, M., … Mortensen, P. B. (2018). The iPSYCH2012 case-cohort sample: new directions for unravelling genetic and environmental architectures of severe mental disorders. Molecular Psychiatry, 23, 6–14.CrossRefGoogle ScholarPubMed
Power, R. A., Verweij, K. J. H., Zuhair, M., Grant, W., Henders, A. K., Heath, A. C., … Martin, N. G. (2014). Genetic predisposition to schizophrenia associated with increased use of cannabis. Molecular Psychiatry, 19, 1201–1204.CrossRefGoogle ScholarPubMed
Ripke, S., Neale, B. M., Corvin, A., Walters, J. T. R. R., Farh, K.-H. H., Holmans, P. A., … O’Donovan, M. C. (2014). Biological insights from 108 schizophrenia-associated genetic loci. Nature, 511, 421–427.Google Scholar
Shi, Y., Lenzi, M., & An, R. (2015). Cannabis liberalization and adolescent Cannabis use: a cross-national study in 38 countries. PLoS ONE, 10, e0143562.CrossRefGoogle ScholarPubMed
Toftdahl, N. G., Nordentoft, M., & Hjorthøj, C. (2016). Prevalence of substance use disorders in psychiatric patients: a nationwide Danish population-based study. Social Psychiatry and Psychiatric Epidemiology, 51, 129–140.CrossRefGoogle ScholarPubMed
Verweij, K. J. H., Abdellaoui, A., Nivard, M. G., Sainz Cort, A., Ligthart, L., Draisma, H. H. M., … Vink, J. M. (2017). Short communication: genetic association between schizophrenia and cannabis use. Drug and Alcohol Dependence, 171, 117–121.CrossRefGoogle ScholarPubMed
Volkow, N. D., Hampson, A. J., & Baler, R. D. (2017). Don't worry, be happy: endocannabinoids and Cannabis at the intersection of stress and reward. Annual Review of Pharmacology and Toxicology, 57, 285–308.CrossRefGoogle ScholarPubMed
Watson, H. J., Yilmaz, Z., Thornton, L. M., Hübel, C., Coleman, J. R. I., Gaspar, H. A., … Bulik, C. M., (2019). Genome-wide association study identifies eight risk loci and implicates metabo-psychiatric origins for anorexia nervosa. Nature Genetics, 51, 1207–1214.CrossRefGoogle ScholarPubMed
Zulauf, C. A., Sprich, S. E., Safren, S. A., & Wilens, T. E. (2014). The complicated relationship between attention deficit/hyperactivity disorder and substance use disorders. Current Psychiatry Reports, 16, 436.CrossRefGoogle ScholarPubMed